SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: JFitnich who wrote (41)5/28/1999 12:49:00 PM
From: scaram(o)uche  Respond to of 447
 
Jason:

Thanks! I'll ask about Freudenthal. I liked the guy (despite the dogma), but there was obviously some realignment toward New York for RS as it became BBRS.

Yes, I think that Mike King is one of the best analysts. However, anyone at an underwriter has vested interests.

Thanks again, very useful information. It's very helpful to have Mike on your team.

Rick



To: JFitnich who wrote (41)5/28/1999 3:14:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 447
 
"left to pursue other opportunities" (eom)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News